Reata, Kyowa Kirin End Bardoxolone CKD Development
Missed Secondary Endpoint In Japan Trial
Reata was expecting positive results from a Phase III study by Japanese licensee for diabetic kidney disease after a US rejection for Alport Syndrome last year, but the US company and Asia partner Kyowa Kirin have now decided to end development in CKD indications after a missed secondary endpoint seen as critical to approval in Japan.
